Treatment with CHEMOSAT has been shown to slow down and, in some cases, halt the progression of hepatic tumours in patients with metastatic uveal melanoma.
Recent UK guidelines and German S3 guidelines have recommended the use of liver directed therapy. 1,2
Delcath have a number of expert CHEMOSAT centres located throughout Europe. Referring a patient is easy, just follow the instructions below.
Download the Referral Form
Contact a CHEMOSAT referral expert
Referral Pathway • Unresectable Hepatic Dominant Uveal Melanoma*3-6
In line with UK & German S3 guidelines, patients presenting with hepatic dominant disease where re-section is not suitable should be considered for liver-directed therapy.
01
Assess Eligibility 7
02/A
Download and
complete the patient referral form
02
Referring
Oncologist
Clinical Assessment
02/B
Identify referral site in consultation with patient
03
Refer to
CHEMOSAT Centre
04
Assessment by
Expert CHEMOSAT
Team
05
CHEMOSAT Treatment every 6-8 weeks
06
Post Treatment
Assessment
*For illustrative purposes only, tests and timelines may vary depending on the hospital and individual clinical needs. Subject to individual centre experience.
Patient Timelines and Touchpoints**7
REFERRAL
Location:
CHEMOSAT Centre / Local Oncology Unit
ASSESSMENT
Location:
CHEMOSAT Centre
TREATMENT
Location:
CHEMOSAT Centre
RE-ASSESSMENT
Location:
CHEMOSAT Centre / Local Oncology Unit / GP
FOLLOW UP
Location:
CHEMOSAT Centre / Local Oncology Unit / GP
** Tests and timelines may vary depending on hospital and individual clinical needs. Subject to individual centre experience.
